GlassScriptPhysician profile
Vanessa Lee
NPI 1104547108
$1,279.27
in general payments reported to CMS, 2019-2025
18 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 89% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $116 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $270.32 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $190.10 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.23 | 2025 | Caplyta |
| Medtronic, INC. | $112.18 | 2025 | Interstim |
| Axsome Therapeutics, INC. | $83.12 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $81.75 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $60.47 | 2025 | Wegovy |
| Neurocrine Biosciences, INC. | $49.02 | 2025 | |
| Exact Sciences Corporation | $42.33 | 2025 | The Cologuard Plus Collection Kit |
| Lundbeck LLC | $39.10 | 2024-2025 | Rexulti |
| Viatris Specialty LLC | $39.02 | 2025 | Yupelri |
| Dexcom, INC. | $35.07 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $34.06 | 2024-2025 | Gemtesa |
| Lilly USA, LLC | $32.39 | 2025 | Zepbound, Mounjaro |
| Sage Therapeutics, LLC | $25.50 | 2025 | Zurzuvae |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $17.10 | 2025 | Opsumit, Uptravi |
| Indivior INC. | $15.40 | 2025 | Sublocade |
| Ascensia Diabetes Care US INC. | $15.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.